FDA’s User-Unfriendly Adverse Event Reporting System: Outdated in the New Transparent World of Social...
A conversation with Brian M. Overstreet, founder and president of Adverse Events, Inc., about the challenges FDA faces in reporting adverse drug events to the public and the impact on patient safety.
The Changing Pharma eDetailing Landscape: The Three Main Ways of Detailing Physicians Online
A chat with Monique Levy, VP Research at Manhattan Research. We discuss how the online pharma promotion landscape has changed, and which types of programs garner the largest audience as well as how the rep relationship is evolving and the role of new technologies such as tablets.
ABPI Digital Update: Insider Reactions
A conversation with Robert Anderson, Head of Digital Communications, Weber Shandwick UK, about the results of an informal survey of pharma clients regarding ABPI's long-awaited digital guidance update.
How Satisfied are Pharma Marketers With Their Digital Efforts? Across Health’s 2011 Digital Barometer
A conversation with Fonny Schenck, Managing Partner/CEO, and Craig Parnell, Managing Partner North America, Across Health, about the 2011 EMEA digital marketing survey for life sciences.
Will e-Patients Force Pharma Elephants to Dance? The Impact of Digital Technology on the...
A conversation with Jonathan Richman, digital strategy development leader for Possible Worldwide, about his presentation
Responding to Unsolicited Requests for Off-Label Information: Pharma Citizen Petition Calls for New Regulations
A conversation with Darshan Kulkarni, Principal Attorney, Kulkarni LLC, focusing on the recent Citizen Petition filed with the FDA by seven major pharmaceutical companies asking for new regulations regarding the dissemination of off-label product information and other communications with healthcare professionals.
The Digital Health Coalition: Solving Real Problems — Mission Possible?
A conversation with Mark Bard, founder of the Digital Health Coalition, regarding the mission of the Coalition and what companies and individuals are involved.
Challenges of Regulating Mobile Medical Apps: Legal and Regulatory Issues You Should Know About
A conversation with Joseph Kim, MD, MPH, VP of Medical Affairs and Technology at Medical Communications Media, Inc., about the rapid development of mobile medical applications and the legal and regulatory issues that physicians, patients, and pharma developers/sponsors should be aware of.
Patient Advocates Take On the FDA: FAMEDS & Genentech Fight for Avastin
A conversation with Terrence Kalley, founder of Freedom of Access to Medicines (FAMEDS), regarding patient advocacy and his organization's fight against FDA's plans to remove the metastatic breast cancer indication for Avastin, a biologic drug produced and marketed by Genentech/Roche.
Implications of Facebook’s Page Commenting Changes
A conversation with Matthew Snodgrass, Social Media Director at WCG, about Facebook's planned changes to its
